To: 5.1.2e [5.1.2e @rki.de]; 5.1.2e (5.1.2e @thl.fi)'[5.1.2e @thl.fi]; 5.1.2e @nijz.si'[5.1.2e @nijz.si]; 5.1.2e [5.1.2e @rivm.nl]; 5.1.2e @mscbs.es'[5.1.2e @mscbs.es]; 5.1.2e 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e 5.1.2e @ecdc.europa.eu]; 5.1.2e 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e 5.1.2e @ecdc.europa.eu]; 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e [5.1.2e @ecdc.europa.eu]; 5.1.2e 5.1.2e @ecdc.europa.eu]; 5.1.2e 5.1.2e [5.1.2e @ecdc.europa.eu]
From: EU NITAG COLLABORATION
Sent: Fri 9/25/2020 10:39:07 AM
Subject: RE: EU NITAG COLLABORATION STEERING COMMITTEE MEETING
Received: Fri 9/25/2020 10:39:13 AM

Dear all,

Please find a draft webinar programme for discussions this afternoon:

Draft programme of webinars hosted by the EU NITAG COLLABORATION AUTUMN 2020

Options for assessing effectiveness against severe disease in vaccinated individuals

Webinar 1: VE Studies in hospital settings (5.1.2e

Webinar 2: VE Studies in Long-term Health Care facilities (staff and residents)

Webinar 3: Assessing safety and effectiveness in health care workers (5.1.2e)

Webinar 4: Modelling COVID-19 vaccination: approaches and considerations (5.1.2e)

Webinar 5: Pooling of data from multi-country studies using the same study protocols, case-definitions and case-report forms and multiple studies using different study protocols (5.1.2e, Epiconcept)

Options for assessing effectiveness against transmission of COVID-19 disease

Webinar 6: VE studies in household studies and other settings

Options for documentation of vaccination

Webinar 7: Documentation of vaccination (individual level and population level) (5.1.2a)

Talk to you soon

5.1.2e

European Centre for Disease Prevention and Control (ECDC)
Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 5.1.2e / Fax +46 (0)8 5.1.2e
www.ecdc.europa.eu

Follow ECDC on:

15 ecdc 2005–2020

-----Original Appointment-----
From: EU NITAG COLLABORATION
Sent: 24 September 2020 18:26

To: 5.1.2e ; 5.1.2e (5.1.2e @thl.fi)'; 5.1.2e @nijz.si'; 5.1.2e @rivm.nl'; 5.1.2e @mscbs.es'; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e
Subject: EU NITAG COLLABORATION STEERING COMMITTEE MEETING
When: 25 September 2020 13:00-14:00 (UTC+01:00) Belgrade, Bratislava, Budapest, Ljubljana, Prague.
Where: For internals room 822

Dear Colleagues,

Welcome to a new Steering Committee meeting and thanks for being available. Please find draft agenda and dial-in details below.

1. Welcome
2. Adoption of the agenda
3. Request from SANTE C3 to develop a paper on vaccine monitoring to be presented to the Health Security Committee with a question on the discussion within the EU NITAG COLLABORATION. Expected to be discussed next week in the HSC meeting, perhaps Thursday 1 October, date still to be confirmed.
4. Living systematic review on COVID-19 vaccines, offer from Germany
5. Draft programme for a series of webinars addressing study designs and study populations for COVID-19 vaccine monitoring studies in the EU/EEA
6. AOB
7. Next meeting

EU NITAG COLLABORATION STEERING COMMITTEE MEETING

Friday 25 September 2020

13:00 | (UTC+02:00) Brussels, Copenhagen, Madrid, Paris | 1 hr

JOIN BY COMPUTER/VIDEO:

If you join by your computer, follow this link: Join

1. Fill in your name
2. If asked, fill in the room/meeting password: 5.1.2h

You now entering the room/meeting.
Welcome!

JOIN BY PHONE:

To join the meting dial this numbe 5.1.2h
Or find your local toll number from this link: Available call-in numbers

Wait for 5 seconds or until instructed.
Then dial the room/meeting number: 5.1.2h

Wait an additional 5 seconds or until instructed.
Dial the password for the room/meeting: 5.1.2h

You now entering the room/meeting.
Welcome!

JOIN BY VIDEO CONFERENCE SYSTEM:

If you join by video conference system dial 5.1.2e @ecdc.webex.com

Dial the password for the room/meeting: 5.1.2h

Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.